We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Regeneron (REGN - Free Report) closed at $771.11, marking a +0.49% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.08%. At the same time, the Dow lost 0.68%, and the tech-heavy Nasdaq lost 0.61%.
Coming into today, shares of the biopharmaceutical company had gained 3.38% in the past month. In that same time, the Medical sector lost 0.75%, while the S&P 500 gained 6.1%.
Regeneron will be looking to display strength as it nears its next earnings release. On that day, Regeneron is projected to report earnings of $10.22 per share, which would represent year-over-year growth of 4.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.07 billion, up 7.42% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $41.09 per share and revenue of $12.78 billion. These results would represent year-over-year changes of -8.65% and +4.96%, respectively.
Investors should also note any recent changes to analyst estimates for Regeneron. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Regeneron is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Regeneron is holding a Forward P/E ratio of 18.67. For comparison, its industry has an average Forward P/E of 19.08, which means Regeneron is trading at a discount to the group.
It is also worth noting that REGN currently has a PEG ratio of 2.07. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.83 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 109, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Regeneron (REGN - Free Report) closed at $771.11, marking a +0.49% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.08%. At the same time, the Dow lost 0.68%, and the tech-heavy Nasdaq lost 0.61%.
Coming into today, shares of the biopharmaceutical company had gained 3.38% in the past month. In that same time, the Medical sector lost 0.75%, while the S&P 500 gained 6.1%.
Regeneron will be looking to display strength as it nears its next earnings release. On that day, Regeneron is projected to report earnings of $10.22 per share, which would represent year-over-year growth of 4.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.07 billion, up 7.42% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $41.09 per share and revenue of $12.78 billion. These results would represent year-over-year changes of -8.65% and +4.96%, respectively.
Investors should also note any recent changes to analyst estimates for Regeneron. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Regeneron is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Regeneron is holding a Forward P/E ratio of 18.67. For comparison, its industry has an average Forward P/E of 19.08, which means Regeneron is trading at a discount to the group.
It is also worth noting that REGN currently has a PEG ratio of 2.07. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.83 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 109, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.